Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012058645 - HETEROCYCLIC TYROSINE KINASE INHIBITORS

Publication Number WO/2012/058645
Publication Date 03.05.2012
International Application No. PCT/US2011/058472
International Filing Date 28.10.2011
IPC
C07D 211/60 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06having no double bonds between ring members or between ring members and non-ring members
36with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
CPC
A61K 31/4545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
Applicants
  • BIOGEN IDEC MA INC. [US]/[US] (AllExceptUS)
  • SUNESIS PHARMACEUTICALS, INC. [US]/[US] (AllExceptUS)
  • HOPKINS, Brian, T. [IE]/[US] (UsOnly)
  • SCOTT, Daniel [US]/[US] (UsOnly)
  • CONLON, Patrick [US]/[US] (UsOnly)
  • JENKINS, Tracy, J. [CA]/[US] (UsOnly)
  • POWELL, Noel [US]/[US] (UsOnly)
  • GUAN, Bing [US]/[US] (UsOnly)
  • CUERVO, Julio, H. [US]/[US] (UsOnly)
  • WANG, Deping [CN]/[US] (UsOnly)
  • TAVERAS, Art [US]/[US] (UsOnly)
Inventors
  • HOPKINS, Brian, T.
  • SCOTT, Daniel
  • CONLON, Patrick
  • JENKINS, Tracy, J.
  • POWELL, Noel
  • GUAN, Bing
  • CUERVO, Julio, H.
  • WANG, Deping
  • TAVERAS, Art
Agents
  • REARICK, John, P.
Priority Data
61/408,33829.10.2010US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HETEROCYCLIC TYROSINE KINASE INHIBITORS
(FR) INHIBITEURS DE TYROSINE KINASE HÉTÉROCYCLIQUES
Abstract
(EN)
The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.
(FR)
L'invention concerne des composés utiles en tant qu'inhibiteurs de kinases de la famille Tec, des compositions de ceux-ci et des procédés d'utilisation associés. Dans des modes de réalisation, l'invention concerne des formulations pharmaceutiques contenant lesdits composés. Dans des modes de réalisation, l'invention concerne un procédé pour diminuer l'activité enzymatique d'un membre des kinases de la famille Tec. Dans des modes de réalisation, de tels procédés consistent à mettre en contact un membre des kinases de la famille Tec avec une quantité suffisante d'un inhibiteur d'un membre des kinases de la famille Tec. Dans des modes de réalisation, l'invention concerne un procédé pour traiter un trouble sensible à l'inhibition de kinases de la famille Tec chez un sujet en ayant besoin.
Also published as
Latest bibliographic data on file with the International Bureau